Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

April 7, 2021

Study Completion Date

October 30, 2023

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Blinatumomab

-Blinatumomab is a bispecific T cell engaging antibody

PROCEDURE

Autologous stem cell transplant

-Standard of care

DRUG

Carmustine

-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.

DRUG

Etoposide

-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.

DRUG

Cytarabine

-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.

DRUG

Melphalan

-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.

PROCEDURE

Peripheral blood draws

-Day +42, Day + 43, Day +56, and Day +100

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Washington University School of Medicine

OTHER